Epigenic

Epigenic secures $60m financing to advance preclinical assets

Epigenic Therapeutics has raised $60m in a Series B funding round, led by Lapam Capital, to advance its preclinical programmes and technology platforms. Existing investors, including Qiming Venture Partners and OrbiMed, also participated in the funding round, alongside new investors such as IFSC.

Epigenic intends to use the funds to advance the clinical development of EPI-003 for chronic hepatitis B and EPI-001 for hypercholesterolemia.

Epigenic co-founder and CEO Bob Zhang said: “We are deeply grateful for the trust and support from both new and existing shareholders. Since our inception, we have remained focused on advancing epigenetic modulation technologies and have achieved remarkable progress in just a few years. We will continue to drive the clinical development of our core pipelines to deliver safe and effective therapies to patients as soon as possible.”

Epigenic is a biotechnology firm specialising in developing next-generation gene modulation therapies using epigenome regulation. Its EPIREG technology platform allows for the precise silencing of target genes through DNA methylation and histone modification, providing a safer alternative to traditional gene-editing techniques that involve DNA cleavage.

Epigenic’s EpiTax platform facilitates targeted delivery of EPIREG tools to the liver and other organs, widening the application of its technology across disease areas. In addition, the company’s AIAID platform supports the molecular design and modulation of epigenetic medicines. With a self-developed model for epigenetics, it supports tasks like target discovery and virtual epigenetic modulation.

The platform leverages artificial intelligence (AI) to accelerate the discovery and optimisation of EPIREG, enhancing the company’s innovation in genetic therapies.

Lapam Capital chairman Zhihua Yu said: “Epigenetic drug development is a highly promising field, and Epigenic has demonstrated outstanding technological advantages and growth potential. The combination of its EPIREG platform and EpiTax delivery system provides a unique solution for disease treatment. With this financing, we believe Epigenic will achieve further breakthroughs in clinical development and technological innovation, solidifying its leadership in epigenetics and bringing transformative therapies to patients worldwide.”